For the latest updates on Gilead’s ongoing response to COVID-19, please click here.

Investor Relations

Contact Us

KiteKonnect®

Press Releases

Filter By Year

2021

April 01, 2021
Kite Submits Supplemental Biologics License Application to U.S. Food and Drug Administration for Tecartus® in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

March 05, 2021
U.S. FDA Approves Yescarta® for Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy

February 10, 2021
Kite Announces New ZUMA-1 Cohort Analysis Evaluating Prophylactic Corticosteroid Use With Yescarta® in Patients With Relapsed or Refractory Large B-cell lymphoma
February 08, 2021
Kite Appoints Frank Neumann as Worldwide Head of Clinical Development

January 19, 2021
Francesco M. Marincola Joins Kite as Worldwide Head of Cell Therapy Research
January 06, 2021
Kite and Oxford BioTherapeutics Establish Cell Therapy Research Collaboration in Blood Cancers and Solid Tumors

Filter By Year